Ascierto PA, Lipson EJ, Dummer R, Larkin J, et al. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol 2023 Feb 13:JCO2202072. doi: 10.1200/JCO.22.02072.
PMID: 36780608